ESLOF:OTC-EssilorLuxottica Société anonyme (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 226.82

Change

-2.40 (-1.05)%

Market Cap

USD 103.48B

Volume

800.00

Analyst Target

USD 160.21
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-22 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOY Essilor International SA

N/A

USD 103.38B
HOCPY Hoya Corp

N/A

USD 42.89B
HOCPF HOYA Corporation

N/A

USD 39.93B
RSMDF Resmed Inc DRC

N/A

USD 30.47B
CLPBF Coloplast A/S

N/A

USD 27.55B
CLPBY Coloplast A

N/A

USD 27.30B
TRUMF Terumo Corporation

N/A

USD 26.63B
TRUMY Terumo Corp ADR

N/A

USD 24.99B
SAUHF Straumann Holding AG

N/A

USD 22.13B
SDMHF Sartorius Stedim Biotech S.A

N/A

USD 21.40B

ETFs Containing ESLOF

C068:F 2.63 % 0.00 %

N/A

N/A
C068:XETRA 2.63 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.87% 86% B+ 69% C-
Dividend Return 2.14% 88% B+ 51% F
Total Return 16.00% 85% B 70% C-
Trailing 12 Months  
Capital Gain 19.69% 88% B+ 74% C
Dividend Return 2.25% 63% D 30% F
Total Return 21.94% 84% B 74% C
Trailing 5 Years  
Capital Gain 89.97% 98% N/A 86% B+
Dividend Return 10.98% 44% F 36% F
Total Return 100.95% 96% N/A 86% B+
Average Annual (5 Year Horizon)  
Capital Gain 11.61% 58% F 58% F
Dividend Return 12.97% 55% F 56% F
Total Return 1.36% 15% F 28% F
Risk Return Profile  
Volatility (Standard Deviation) 21.92% 90% A- 84% B
Risk Adjusted Return 59.14% 97% N/A 91% A-
Market Capitalization 103.48B 100% F 99% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

What to not like:
Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.